Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranibizumab Regimens for RVO-ME
NCT04062370Phase 4Unknown
- Sponsor
- Sun Yat-sen University
- Start
- Oct 2019
- Primary completion
- Aug 2022
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of ranibizumab in macular edema and retinal vein occlusion (RVO), sponsored by Sun Yat-sen University. Primary endpoints: best-corrected visual acuity at 6 months and central macular thickness at 6 months. Status: unknown.
02
Drugs
ranibizumab
03
Conditions
macular edemaretinal vein occlusion (RVO)
Beyond the preview
Go deeper on NCT04062370.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04062370.